Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.82 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.64 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.64 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775527 | 0.91 | MAP2K1 (0.81) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL14205715 | 0.90 | MAP2K1 (0.71) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL1775851 | 0.90 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL1775115 | 0.89 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL1777775 | 0.89 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL1775117 | 0.89 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL219266 | 0.84 | MAP2K1 (0.70) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL1775958 | 0.82 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL12600067 | 0.82 | MAP2K1 (0.67) | MAP2K1MAP2K2 | |
| SCHEMBL219859 | 0.82 | MAP2K1 (0.67) | MAP2K1MAP2K2MAP2K5EIF2AK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943659-B2 | cancerous hyperproliferative disorders; 5-Acetyl-2-(2-fluoro-4-iodo-phenylamino)-1H-pyrrole-3-carboxylic acid; 2-acetyl-5-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-imidazole-4-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | claimed |
| EP-2113500-A1 | MAPK/ERK kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2009-11-04 | — | — | EP | claimed |
| US-20080188453-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA CALIFORNIA, INC. | 2008-08-07 | — | — | US | claimed |
| US-7943659-B2 | cancerous hyperproliferative disorders; 5-Acetyl-2-(2-fluoro-4-iodo-phenylamino)-1H-pyrrole-3-carboxylic acid; 2-acetyl-5-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-imidazole-4-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943659-B2 | cancerous hyperproliferative disorders; 5-Acetyl-2-(2-fluoro-4-iodo-phenylamino)-1H-pyrrole-3-carboxylic acid; 2-acetyl-5-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-imidazole-4-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943659-B2 | cancerous hyperproliferative disorders; 5-Acetyl-2-(2-fluoro-4-iodo-phenylamino)-1H-pyrrole-3-carboxylic acid; 2-acetyl-5-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-imidazole-4-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| EP-2113500-A1 | MAPK/ERK kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-20080188453-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA CALIFORNIA, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188453-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA CALIFORNIA, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188453-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA CALIFORNIA, INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188453-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | MAP2K1 44/4885MAP2K2 43/4885MAP2K5 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.